NC-HITHIUM
21.11.2023 15:01:31 CET | Business Wire | Press release
Stationary battery manufacturer Hithium has signed an initial cooperation agreement with FlexGen, the leading energy storage software integration and service provider. The companies agreed to purchasing targets over the next three years, with the North Carolina-based FlexGen aiming to support the procurement of 10 GWh of battery capacity from Hithium either through project efforts or indirectly from partners utilizing FlexGen’s energy management system (EMS), the HybridOS software and controls. At the same time, Hithium committed to the goal of securing, directly or through partners, FlexGen’s EMS for projects with a combined 15 GWh of capacity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121630058/en/
(Photo: Business Wire)
As part of the agreement, FlexGen will also be an authorized service provider for Hithium in the United States, accelerating the speed of service to asset owners and enhancing asset uptime. Keeping energy storage assets available for owners is a key shared value described by both parties.
Hithium Head of Global Business Mizhi Zhang commented: “We are very excited for the opportunity to work more closely with the team at FlexGen and benefit from their expertise in the U.S. energy storage market. The cutting-edge capabilities of their EMS will also bring significant added value to our product offering.”
Yann Brandt, Chief Commercial Officer of FlexGen said: “FlexGen and our partners share the vision of flexible, high performance battery storage assets. Hithium’s technology, tailor-made for utility-scale storage, packaged with our HybridOS operating system, provides great value to our mutual customers.”
FlexGen designs multi-megawatt energy storage systems, integrated with its proprietary energy management system, the HybridOS, along with managing procurement, testing, commissioning, and offering monitoring and maintenance services.
Hithium manufactures high-efficiency battery products, from cells like its 314 Ah with an 11,000-cycle life, to energy storage systems including its newly released 5 MWh ∞block. Based in Xiamen, China, with operations in the U.S., Australia, UAE, and Europe, the company has shipped 11 GWh of capacity since being founded in 2019.
About HiTHIUM
Founded in 2019, HiTHIUM is a leading manufacturer of top-quality stationary energy storage products for utility-scale as well as commercial and industrial applications. With four distinct R&D centers and multiple “intelligent” production facilities, HiTHIUM’s innovations include groundbreaking safety improvements to its lithium-ion batteries as well as increases in lifecycle. With many decades of cumulative experience in the field among its founders and senior executives, HiTHIUM leverages its specialization in BESS to deliver partners and customers unique advances in energy storage. The company is based in Xiamen, China, with further locations for production, research, or sales in Shenzhen, Chongqing, Munich, and California. HiTHIUM has shipped 11 GWh of battery capacity, 5 GWh in 2022 alone, and is expanding its production capacity to 70 GWh by the end of 2023.
About FlexGen Power Systems, Inc.
Based in Durham, N.C., FlexGen is a leading integration services and software technology provider for energy storage solutions in the United States and globally. FlexGen designs and integrates storage solutions and the software platform that is enabling today’s energy transition. Leveraging its best-in-class energy management software and digital controls, FlexGen delivers utility-scale storage projects integrated with traditional and renewable power generation globally. The company‘s clients and partners include the most technically and commercially demanding developers, utilities, government agencies and industrial companies in the world. To learn more, visit www.site.flexgen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121630058/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom